US9013841070 - Common Stock
2SEVENTY BIO INC
NASDAQ:TSVT (5/21/2024, 7:00:02 PM)
After market: 4.38 0 (0%)4.38
0 (0%)
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 425 full-time employees. The company went IPO on 2021-10-18. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The Company’s advancing multiple clinical programs, including SC-DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia (AML), and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, or B-NHL, as well as multiple preclinical programs, including bbT4015, an engineered CAR T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb, the Company is delivering Abecma to multiple myeloma patients in the United States.
2SEVENTY BIO INC
60 Binney Street
Cambridge MASSACHUSETTS
P: 13394999300
Employees: 425
Website: https://www.2seventybio.com/
TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Here you can normally see the latest stock twits on TSVT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: